Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. It affects over six million individuals in the 8MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, and Australia) and this prevalence is expected to grow to just shy of 7 million individuals by 2025. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2015 and 2025. With the anti-TNFs as extremely effective for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars launch across the 8MM and begin to gain traction in these markets.
Key players listed in the report are AbbVie, Pfizer, Amgen, Johnson & Johnson, Eli Lilly, Bristol-Myers Squibb, UCB, Roche, GlaxoSmithKline, Sanofi, AstraZeneca- MedImmune, Astellas, Daiichi Sankyo, Samsung Bioepis, Sandoz.
Requets a sample of RA Industry @ http://www.orbisresearch.com/contacts/request-sample/289566 .
- Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the RA biologics and biosimilars markets.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s Olumiant (baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Pfizer’s Inflectra/Remsima, Samsung Bioepis/Biogen/Merck’s Flixabi and Benepali, Sandoz’s Erelzi, and Amgen’s Amjevita).
- Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Purchase a copy of rheumatoid arthritis (RA) market report @ http://www.orbisresearch.com/contact/purchase/289566 .
Scope of the Urology Endoscopes-Global Analysis and Market Forecasts
- Competitive assessment: Currently marketed urology endoscopes and evolving competitive landscape
- In-depth analysis of unmet needs and adoption trends of different urology endoscopes
- Insightful review of the key industry drivers, opportunities, restraints and challenges.
- Annualized total urology endoscopes market revenue by segment and market outlooks from 2013-2023.
- Other key topics covered include strategic competitive assessment, identification of unmet needs, and market dynamics.
Key companies listed in the Urology Endoscopes Industry report are Boston Scientific Corporation, Cogentix Medical, Inc., Karl Storz GmbH & Co., Olympus Corporation, Pentax Medical, Richard Wolf GmbH, Stryker Corporation.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the urology endoscopes market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the urology endoscopes market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific urology endoscopes market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Request a sample of the Urology Endoscopes Market report @ http://www.orbisresearch.com/contacts/request-sample/289575 .
Urology Endoscopes include -
Growth in the urology endoscopes market is driven by -
- Technological advancements in endoscopes
- Rising prevalence of urology disorders
The global market for urology endoscopes is led by -
- Olympus Corporation
- Karl Storz GmbH & Co.
- Pentax Medical Company
- Richard Wolf GmbH
- Stryker Corporation
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Company Name: Orbis Research
Contact Person: Hector Costello
Phone: +1 (214) 884-6817
Address:4144N Central Expressway, Suite 600
Country: United States